Core Viewpoint - Arcturus Therapeutics has been upgraded to a Zacks Rank 2 (Buy) due to an upward trend in earnings estimates, which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Movement - The Zacks rating system emphasizes the importance of changing earnings estimates in determining near-term stock price movements, making it a valuable tool for investors [2][4]. - The correlation between earnings estimate revisions and stock price movements is strong, particularly due to the actions of institutional investors who adjust their valuations based on these estimates [4]. Business Outlook and Investor Sentiment - The upgrade in rating for Arcturus Therapeutics reflects an improvement in the company's underlying business, suggesting that investors may respond positively by driving the stock price higher [5]. - Analysts have raised their earnings estimates for Arcturus Therapeutics, with the Zacks Consensus Estimate increasing by 45.1% over the past three months [8]. Zacks Rank System - The Zacks Rank system categorizes stocks based on earnings estimates into five groups, with a strong historical performance, particularly for Zacks Rank 1 stocks, which have averaged a +25% annual return since 1988 [7]. - Arcturus Therapeutics' upgrade to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, indicating a strong potential for market-beating returns in the near term [10].

Core Insights - Arcturus Therapeutics and CSL Seqirus reported positive results from a 12-month follow-up analysis of their sa-mRNA COVID-19 vaccine, ARCT-154, leading to a stock increase of 5.4% and an additional 2.5% in after-market hours [1][2] Vaccine Efficacy - ARCT-154 demonstrated a stronger and longer-lasting immune response compared to the conventional mRNA vaccine Comirnaty, with effective results against various strains using only one-sixth of the dosage (5 μg vs 30 μg) [2] - The bivalent vaccine ARCT-2301 also showed enhanced immune responses compared to Comirnaty, persisting for up to six months against key variants [2] Market Performance - Year-to-date, Arcturus shares have decreased by 26.4%, contrasting with a 1.8% decline in the industry [4] Regulatory Approvals - ARCT-154 received approval in Japan in November 2023 as the first sa-mRNA COVID-19 vaccine for adults, with an updated formulation targeting variant JN.1 also approved [4] - The FDA approved updated mRNA vaccines from Pfizer/BioNTech and Moderna targeting the KP.2 strain, with emergency use authorization for low-dose formulations for younger individuals [6] Pipeline Developments - Arcturus is advancing its pipeline with ARCT-032 for cystic fibrosis, having received FDA clearance for its IND application, and is set to begin a phase II study [8] - Another candidate, ARCT-810, is in phase II for ornithine transcarbamylase deficiency, with potential for growth through successful development [9] Company Ranking - Arcturus currently holds a Zacks Rank 1 (Strong Buy), indicating strong market confidence [10]

Head-to-head data, presented at OPTIONS XII for the Control of Influenza Conference, demonstrates advantage of sa-mRNA over conventional mRNA in duration of immune response; Results highlight CSL and Arcturus Therapeutics' commitment to advancing COVID-19 vaccine innovation to protect public health.WALTHAM, Mass. and SAN DIEGO, Sept. 30, 2024 /PRNewswire/ -- Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) and self-amplifying messenger RNA (sa-mRNA) pioneer Arcturus Therapeutics (Nasdaq: ARCT) today a ...

Arcturus Therapeutics Holdings Inc. (ARCT) is engaged in developing messenger RNA (mRNA) medicines and vaccines based on its innovative and enabling technologies.San Diego, CA-based Arcturus has developed the first self-amplifying mRNA (sa-mRNA) COVID-19 vaccine, Kostaive, in the world. The company has a collaboration agreement with renowned vaccine company CSL Seqirus for making innovative mRNA vaccines.Last week, Arcturus and CSL announced that Japan's Ministry of Health, Labor and Welfare (MHLWs) approve ...

Arcturus Therapeutics (ARCT) closed the last trading session at $21.10, gaining 2.7% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $66.75 indicates a 216.4% upside potential.The average comprises eight short-term price targets ranging from a low of $18 to a high of $140, with a standard deviation of $35.48. While the lowest estimate indicates a decline of 14.7% from the current p ...

Peter HansenI have previously written about Arcturus (NASDAQ:ARCT). This is one of my preferred biotech startup plays. The company is close to the commercial launch of the Kostaive self-amplifying mRNA COVID-19 vaccine. Meiji, their partners in Japan, is responsible for the regulatory application so that the vaccine complies with the regulatory demands for the 2024-2025 flu season in Japan. The phase 3 data have revealed a strong immune response, validating the STARR Platform for self-amplifying mRNA va ...

cs UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 per share ARCT The NASDAQ Stock Market LLC FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to C ...

Arcturus Therapeutics Announces Second Quarter 2024 Financial Update and Pipeline Progress IND submitted for Phase 2 trial of ARCT-032 targeting cystic fibrosis (CF) ARCT-810 (OTC deficiency) Phase 2 interim data on track for Q4 Kostaive® on track for Q4 commercial launch in Japan Investor conference call at 4:30 p.m. ET today SAN DIEGO--(BUSINESS WIRE)--August. 5, 2024-- Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global messenger RNA medicines company focused on the de ...

Dragon Claws/iStock via Getty Images Arcturus (NASDAQ:ARCT) is one of my top picks for the biotech sector as I have outlined in a previous piece. The stock market performance is a testament to the bullish rationale in this stock. Seeking Alpha The differentiating factor of this company, vis-à-vis other similar peers in the sector, is that it is not exactly a cash-burner, even without deriving revenue from any proprietary commercial product so far. The differentiating element is that the company has be ...

Data follow the approval of the world's first self-amplifying (sa-mRNA) COVID-19 vaccine for adults in Japan.  These results add to recently published data on ARCT-154 demonstrating superior immunogenicity to Omicron BA 4/5 compared to conventional mRNA COVID-19 vaccine booster and follow-up data demonstrating longer duration of immunity compared to traditional COVID-19 mRNA vaccine booster. KING OF PRUSSIA, Pa. and SAN DIEGO, May 20, 2024 /PRNewswire/ -- Global biotechnology leader CSL (ASX:CSL; USOTC:CSL ...